<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03433196</url>
  </required_header>
  <id_info>
    <org_study_id>HS-25-III-02</org_study_id>
    <nct_id>NCT03433196</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of the HS-25 Combination With Atorvastatin in Subjects With Hypercholesterolemia in Coronary Heart Diseases</brief_title>
  <acronym>HS-25-III-02</acronym>
  <official_title>Randomized,Double Blind,Double Dummy, Multi-center Study of Efficacy and Safety of HS-25 Combination With Atorvastatin in Subjects With Hypercholesterolemia in Coronary Heart Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Hisun Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Hisun Pharmaceutical Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy of HS-25 (20mg) in reducing low density lipoprotein-cholesterol
      (LDL-C) levels after a 12-week period of treatment in combination with Atorvastatin in
      subjects with hypercholesterolemia and coronary heart diseases; To determine the safety of
      HS-25 (20mg) combination with Atorvastatin in subjects with hypercholesterolemia and coronary
      heart diseases
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 7, 2016</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double blind, Double dummy</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change of LDL-C</measure>
    <time_frame>2,4,8,12 weeks</time_frame>
    <description>Percent change from baseline in LDL-C after 2,4,8,12 weeks of double-blind treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change of Non-HDL-C</measure>
    <time_frame>2,4,8,12 weeks</time_frame>
    <description>Percent change from baseline in Non-HDL-C after 2,4,8,12 weeks of double-blind treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change of TC,TG,ApoB,ApoAI</measure>
    <time_frame>2,4,8,12 weeks</time_frame>
    <description>Percent change from baseline in TC,TG,ApoB and ApoAI after 2,4,8,12 weeks of double-blind treat</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Hypercholesterolemia in Coronaory Heart Disease</condition>
  <arm_group>
    <arm_group_label>HS-25 and Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HS-25 20mg, Atorvastatin 10mg, Placebo of Atorvastatin 1 tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin 20mg, Placebo of HS-25 2 tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HS-25 and Atorvastatin</intervention_name>
    <description>HS-25 20mg (2 tablets), Atorvastatin 10mg, Placebo of Atorvastatin 1 tablet oral, once daily</description>
    <arm_group_label>HS-25 and Atorvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin 20mg (2 tablets), Placebo of HS-25 2 tablets, oral, once daily</description>
    <arm_group_label>Atorvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diet control for 14 weeks, Atorvastatin 10mg once daily for 6 weeks or above;

          -  The average of both qualifying values must be in the range of 2.07 mmol/L to 3.36
             mmol/L. Run-in (Visit 2 and Visit 3) and the Visit 3 value must be within 12% of the
             value at Visit 2, higher or lower;

          -  Must meet the one of diseases as following:

               1. Subjects who have stable coronary heart disease;

               2. Subjects who diagnosed ischemic stroke in stable condition;

               3. Subjects who diagnosed as Diabetes mellitus

        Exclusion Criteria:

          -  history of Severe Endiocrine disease (for example Thyroid function abnormal);

          -  History of advanced cancer

          -  Arrhythmias need to be treated by medications history of Hemorrhagic stroke;

          -  Cardiac dysfunction;

          -  Unstable ASCVD;

          -  History of organ transplant;

          -  Hypersensitive to HS-25 or place;

          -  uncontrolled or new diagnosed diabetes mellitus;

          -  HCV and HBsAg positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Litong Qi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2018</study_first_submitted>
  <study_first_submitted_qc>February 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2018</study_first_posted>
  <last_update_submitted>February 8, 2018</last_update_submitted>
  <last_update_submitted_qc>February 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

